nSpire Health

nSpire Health developed and commercialized a suite of advanced respiratory diagnostic devices, home monitoring solutions, and electronic patient-reported outcome tools. Their products have been widely adopted in global clinical trials for asthma, COPD, cystic fibrosis, and other respiratory conditions. The company’s core lab services supported over 225 clinical studies across more than fifty countries prior to the acquisition of its clinical trial division by iCardiac Technologies in August 2015. Their digital platforms such as PiKoLogic achieved high compliance rates (>98%) for subject data collection during trials. The company's focus has been on improving accuracy of lung function measurement both at home and in clinics to accelerate drug development and improve patient outcomes.